文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

应急情况下疫苗临床试验受试者招募新方法的探索与应用

[Exploration and application of a novel attempt to recruit participants in clinical trials of vaccines under the emergency].
PubMed 文献 · Zhonghua Yu Fang Yi Xue Za Zhi · 2020-01-01

本研究评估了通过网站和自媒体发布招募通知、结合主动申报系统与电话回访的疫苗临床试验受试者招募新方法。结果显示Ⅰ期和Ⅱ期分别登记4 819和5 132名志愿者,电话确认参加率分别为35.00%和67.20%,到达现场者抗体阳性率为6.00%和4.31%,该方法高效可靠。

要点

  • 主动申报系统结合电话回访可高效初筛志愿者,Ⅱ期电话确认参加率达67.20%。
  • Ⅰ期和Ⅱ期登记志愿者均以20~39岁年龄段居多,分别占66.63%和77.28%。
  • 到达现场志愿者新冠抗体阳性率Ⅰ期6.00%、Ⅱ期4.31%。

核心结论

  • 该受试者招募新方法高效、可靠,Ⅰ期为Ⅱ期做了良好典范。
  • 受试者中长期依从性及意愿与行为分离情况仍需进一步研究。

研究设计与样本

  • 通过网站和自媒体在武汉局部地区发布招募通知,引导有意向者登录主动申报系统预约登记和健康主动申报。
  • 主动申报系统评估志愿者并划分风险等级以初步排除不符合纳入标准者,研究者对初评合格者电话回访,组织前往接种现场,最后严格体检筛查确定最终受试者。

主要发现

  • Ⅰ期和Ⅱ期招募系统分别登记4 819和5 132名,男性2 912名(60.43%)和2 887名(56.25%),女性1 907名(39.57%)和2 245名(43.75%)。
  • Ⅰ期和Ⅱ期均以20~39岁年龄段居多,分别有3 211名(66.63%)和3 966名(77.28%);武汉13个区均有居民意向参与。
  • Ⅱ期初步通过人数高于Ⅰ期:男性2 047名(70.28%)和2 135名(73.95%),女性1 083名(56.80%)和1 472名(65.57%)。
  • Ⅰ期和Ⅱ期分别电话回访440和689名,电话确认参加人数约154名(35.00%)和463名(67.20%)。
  • 到达疫苗接种现场志愿者分别有201和603名,新冠病毒抗体阳性分别有12和26例,抗体阳性率6.00%和4.31%。

临床怎么用

  • 应急情况下可借助网络平台发布招募通知并利用主动申报系统进行初步风险评估和排除不符合纳入标准者。
  • 电话回访可进一步确认志愿者意愿并组织前往接种现场,最终通过严格体检筛查确定受试者。

局限性

  • 受试者的中长期依从性仍需进一步研究。
  • 意愿与行为分离的情况仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate and share the novel method for recruiting participants in clinical trials of vaccines in emergency situations. Methods: To publish recruitment notice in local areas of Wuhan through websites and medium, and guide interested persons to log in to the"Clinical Trials of SARS-CoV-2 Vaccine Reservation and Health Declaration System"to appoint and register their health information. The "Health Declaration System" provides each volunteer evaluation and risk levels to preliminarily exclude those who do not meet the inclusion criteria. Researchers review the qualified volunteers by telephone, organize them to go to the vaccination site, and finally conduct a strict medical screening to determine the final subjects. Results: A total of 4 819 people and 5 132 people registered in the Phase Ⅰ and Phase Ⅱ recruitment system respectively, with men 2 912 (60.43%) and 2 887 (56.25%) more than women 1 907 (39.57%) and 2 245 (43.75%), mostly in the 20-39 age group, with 3 211 (66.63%) and 3 966 (77.28%). All 13 districts in Wuhan have interested residents to participate clinical research.The initial qualified rate of the Phase Ⅱ recruitment system was higher than that of Phase Ⅰ, with men 2 047 (70.28%) and 2 135(73.95%), higher than women 1 083 (56.80%) and 1 472 (65.57%); 440 and 689 people were reviewed by telephone in Phase Ⅰ and Phase Ⅱ respectively, and the number of verified volunteers was about 440 (35.00%) and 689 (67.20%); Of the 201 603 people who arrived at the vaccination site, 12 and 26 of them were positive for the SARS-CoV-2 antibody with an antibody positive rate of 6.00% and 4.31% respectively. Conclusion: The novel method for recruiting subjects in this clinical study is efficient and reliable, and the recruitment situation of Phase Ⅰ had set a good example for Phase Ⅱ but the medium-and long-term compliance of subjects and the separation of willingness and behaviors still need to be further studied. 目的: 评估在应急情况下疫苗临床试验受试者招募的新方法。 方法: 通过网站和自媒体等在武汉局部地区发布招募通知,引导有意向者登录“新冠疫苗临床试验预约登记和健康主动申报系统”(简称主动申报系统)进行预约登记和健康主动申报,主动申报系统对每名志愿者进行评估并划分风险等级以初步排除不符合纳入标准的志愿者,研究者对初评合格的志愿者进行电话回访,组织志愿者前往疫苗接种现场,最后进行入组前的严格体检筛查以确定最终受试者。 结果: Ⅰ和Ⅱ期招募系统分别共登记4 819和5 132名,男性2 912(60.43%)和2 887名(56.25%),多于女性的1 907(39.57%)和2 245名(43.75%),均以20~39岁年龄段居多,分别有3 211(66.63%)和3 966名(77.28%);武汉13个区均有居民意向参与临床研究,Ⅱ期招募系统初步通过人数高于Ⅰ期,男性通过人数2 047(70.28%)和2 135名(73.95%),高于女性1 083(56.80%)和1 472名(65.57%);Ⅰ和Ⅱ期分别电话回访440和689名,电话确认参加人数约154(35.00%)、463名(67.20%);到达疫苗接种现场志愿者分别有201和603名,新冠病毒抗体阳性分别有12和26例,抗体阳性率为6.00%和4.31%。 结论: 本研究受试者招募的新方法高效、可靠,Ⅰ期的招募情况为Ⅱ期做了良好的典范,但受试者的中长期依从性以及出现的意愿与行为分离的情况仍需进一步研究。.

来源:Zhonghua Yu Fang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Jiang HDC, Wang Z, Wang L, et al. [Exploration and application of a novel attempt to recruit participants in clinical trials of vaccines under the emergency]. Zhonghua Yu Fang Yi Xue Za Zhi. 2020. PMID: 32907286. doi:10.3760/cma.j.cn112150-20200427-00653

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。